BR9913303A - High affinity antibodies - Google Patents
High affinity antibodiesInfo
- Publication number
- BR9913303A BR9913303A BR9913303-2A BR9913303A BR9913303A BR 9913303 A BR9913303 A BR 9913303A BR 9913303 A BR9913303 A BR 9913303A BR 9913303 A BR9913303 A BR 9913303A
- Authority
- BR
- Brazil
- Prior art keywords
- samples
- sample
- antibody
- incubation
- hour
- Prior art date
Links
- 238000011534 incubation Methods 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 abstract 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 abstract 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 abstract 1
- 238000002835 absorbance Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Patente de Invenção: "ANTICORPOS DE ALTA AFINIDADE" Anticorpos monoclonais de alta afinidade, em que a afinidade é caracterizada por: (i) incubação de uma primeira e de uma segunda amostras do anticorpo em cavidades de placas de microtítulo revestidas com antígeno, em uma concentração escolhida para estar dentro da parte linear de uma curva padrão, em pH 7, 2, por 1 hora, à 37 °C; (ii) remoção do anticorpo não-ligado de ambas as amostras; (iii) incubação da primeira amostra com PBS, em pH 7, 2, por 1 hora, à 37 °C, e redução do pH da segunda amostra até pH 3 ou abaixo, e incubação por 1 hora, à 37 °C; (iv) remoção do anticorpo não-ligado de ambas as amostras; (v) incubação de ambas as amostras com conjugado de antianticorpo fosfatase alcalina, por 1 hora, à 37 °C; (vi) remoção do conjugado não-ligado de ambas as amostras; e (vii) adição de substrato de PNPP às amostras, medição da absorbância das amostras à 405 nm, e determinação da quantidade de anticorpo ligado ao antígeno, em que a quantidade ligada na segunda amostra é >50% daquela da primeira amostra.Invention Patent: "HIGH AFFINITY ANTIBODIES" High affinity monoclonal antibodies, where affinity is characterized by: (i) incubation of a first and a second antibody sample in antigen-coated microtiter plate wells, in a concentration chosen to be within the linear part of a standard curve, at pH 7, 2, for 1 hour, at 37 ° C; (ii) removal of unbound antibody from both samples; (iii) incubation of the first sample with PBS, at pH 7, 2, for 1 hour, at 37 ° C, and reducing the pH of the second sample to pH 3 or below, and incubation for 1 hour, at 37 ° C; (iv) removal of unbound antibody from both samples; (v) incubation of both samples with anti-antibody alkaline phosphatase conjugate, for 1 hour, at 37 ° C; (vi) removing the unbound conjugate from both samples; and (vii) adding PNPP substrate to the samples, measuring the absorbance of the samples at 405 nm, and determining the amount of antibody bound to the antigen, where the amount bound in the second sample is> 50% of that of the first sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9818915.2A GB9818915D0 (en) | 1998-08-28 | 1998-08-28 | Antibodies |
| PCT/GB1999/002729 WO2000012556A1 (en) | 1998-08-28 | 1999-08-20 | High-affinity antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9913303A true BR9913303A (en) | 2001-10-09 |
Family
ID=10838074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9913303-2A BR9913303A (en) | 1998-08-28 | 1999-08-20 | High affinity antibodies |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1107990A1 (en) |
| JP (1) | JP2002525082A (en) |
| KR (1) | KR20010089174A (en) |
| CN (1) | CN1315966A (en) |
| AU (1) | AU5435099A (en) |
| BG (1) | BG105294A (en) |
| BR (1) | BR9913303A (en) |
| CA (1) | CA2340865A1 (en) |
| EA (1) | EA200100287A1 (en) |
| GB (1) | GB9818915D0 (en) |
| HR (1) | HRP20010149A2 (en) |
| HU (1) | HUP0103233A3 (en) |
| ID (1) | ID28905A (en) |
| IL (1) | IL141523A0 (en) |
| MX (1) | MXPA01002248A (en) |
| NO (1) | NO20011006L (en) |
| PL (1) | PL346472A1 (en) |
| TR (1) | TR200100643T2 (en) |
| WO (1) | WO2000012556A1 (en) |
| YU (1) | YU15401A (en) |
| ZA (1) | ZA200101573B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0031284D0 (en) * | 2000-12-21 | 2001-01-31 | Ks Biomedix Ltd | High affinity antibodies |
| GB0112844D0 (en) * | 2001-05-25 | 2001-07-18 | Psimei Pharmaceuticals Plc | Neutron capture therapy |
| WO2003105757A2 (en) * | 2002-06-12 | 2003-12-24 | Genencor International, Inc. | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| US20030232401A1 (en) * | 2002-06-12 | 2003-12-18 | Pugia Michael J. | Bacterial test method by glycated label binding |
| WO2005058236A2 (en) * | 2003-12-12 | 2005-06-30 | Genencor International, Inc. | Cab molecules |
| CN111848790B (en) * | 2020-08-07 | 2022-02-22 | 上海交通大学 | Bovine-derived single-chain antibody for resisting staphylococcus aureus and preparation and application thereof |
| CN112724255A (en) * | 2021-01-28 | 2021-04-30 | 成都金昆生物科技有限公司 | Small molecule antibodies targeting carcinoembryonic antigens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5081235A (en) * | 1989-07-26 | 1992-01-14 | City Of Hope | Chimeric anti-cea antibody |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
-
1998
- 1998-08-28 GB GBGB9818915.2A patent/GB9818915D0/en not_active Ceased
-
1999
- 1999-08-20 ID IDW20010714A patent/ID28905A/en unknown
- 1999-08-20 KR KR1020017002434A patent/KR20010089174A/en not_active Application Discontinuation
- 1999-08-20 HU HU0103233A patent/HUP0103233A3/en unknown
- 1999-08-20 BR BR9913303-2A patent/BR9913303A/en not_active IP Right Cessation
- 1999-08-20 EP EP99940355A patent/EP1107990A1/en not_active Withdrawn
- 1999-08-20 IL IL14152399A patent/IL141523A0/en unknown
- 1999-08-20 CA CA002340865A patent/CA2340865A1/en not_active Abandoned
- 1999-08-20 YU YU15401A patent/YU15401A/en unknown
- 1999-08-20 JP JP2000571062A patent/JP2002525082A/en active Pending
- 1999-08-20 PL PL99346472A patent/PL346472A1/en not_active Application Discontinuation
- 1999-08-20 TR TR2001/00643T patent/TR200100643T2/en unknown
- 1999-08-20 EA EA200100287A patent/EA200100287A1/en unknown
- 1999-08-20 WO PCT/GB1999/002729 patent/WO2000012556A1/en not_active Application Discontinuation
- 1999-08-20 MX MXPA01002248A patent/MXPA01002248A/en unknown
- 1999-08-20 CN CN99810367A patent/CN1315966A/en active Pending
- 1999-08-20 AU AU54350/99A patent/AU5435099A/en not_active Abandoned
-
2001
- 2001-02-26 BG BG105294A patent/BG105294A/en unknown
- 2001-02-26 ZA ZA200101573A patent/ZA200101573B/en unknown
- 2001-02-27 NO NO20011006A patent/NO20011006L/en not_active Application Discontinuation
- 2001-02-28 HR HR20010149A patent/HRP20010149A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1315966A (en) | 2001-10-03 |
| ID28905A (en) | 2001-07-12 |
| KR20010089174A (en) | 2001-09-29 |
| AU5435099A (en) | 2000-03-21 |
| ZA200101573B (en) | 2002-02-26 |
| GB9818915D0 (en) | 1998-10-21 |
| EP1107990A1 (en) | 2001-06-20 |
| NO20011006D0 (en) | 2001-02-27 |
| JP2002525082A (en) | 2002-08-13 |
| BG105294A (en) | 2001-12-29 |
| IL141523A0 (en) | 2002-03-10 |
| NO20011006L (en) | 2001-02-27 |
| HUP0103233A2 (en) | 2001-12-28 |
| HRP20010149A2 (en) | 2002-02-28 |
| MXPA01002248A (en) | 2002-05-08 |
| WO2000012556A1 (en) | 2000-03-09 |
| EA200100287A1 (en) | 2001-08-27 |
| HUP0103233A3 (en) | 2003-10-28 |
| TR200100643T2 (en) | 2001-07-23 |
| YU15401A (en) | 2003-07-07 |
| CA2340865A1 (en) | 2000-03-09 |
| PL346472A1 (en) | 2002-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McCoy Jr et al. | Enzyme-linked lectin assay (ELLA): use of alkaline phosphatase-conjugated Griffonia simplicifolia B4 isolectin for the detection of α-D-galactopyranosyl end groups | |
| FI891012A0 (en) | Method and instrument for compensating for interfering factors in immunoassays | |
| ES524101A0 (en) | AN IMMUNOCROMATOGRAPHIC METHOD FOR DETERMINING THE PRESENCE OF A CERTAIN ANALYZABLE COMPONENT IN A SAMPLE CONTAINING SUCH COMPONENT. | |
| CA2235316C (en) | A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd) | |
| DK129986A (en) | MONOCLONAL ANTIBODY FOR IMMUNKEMIC ANALYSIS | |
| BR9714365A (en) | Detection of specific antigen igm | |
| BR9906351A (en) | Antibody assay method and antibody assay device | |
| US5139932A (en) | Method and a kit for the diagnosis of iga nephropathy | |
| EP0535162B1 (en) | Analyte variant analysis | |
| JPH05504481A (en) | Improved antibody-enzyme direct conjugate and method for producing the same | |
| KR900002075A (en) | Methods and reagents for specifically binding substances | |
| BR9913303A (en) | High affinity antibodies | |
| Teitsson et al. | Use of monoclonal antibodies and F (ab′) 2 enzyme conjugates in ELISA for IgM, IgA and IgG rheumatoid factors | |
| WO2003046140A3 (en) | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | |
| Halbert et al. | A quantitative enzyme immunoassay for IgM rheumatoid factor using human immunoglobulin G as substrate | |
| Ishiguro et al. | Sensitive solid phase enzyme immunoassay for human IgA, secretory IgA, and secretory component | |
| FR2778744B1 (en) | IMMUNOLOGICAL ASSAY FOR HUMAN CHROMOGRANIN (CGA) ANTIBODIES, REAGENTS AND KITS FOR USE IN THIS ASSAY | |
| BR9913837A (en) | Formulation of salmonella antigen and kits for the detection of salmonella antibodies | |
| Voshall et al. | Effect of albumin on serum digoxin radioimmunoassays | |
| CA2434694A1 (en) | Detection and quantification of cripto-1 | |
| BR9913770A (en) | Test procedure for determining cobalamin bound to transcobalamin ii (tcii) in a body sample, kit for use in a diagnostic assay, and use of holo-tc ii | |
| KR880013013A (en) | Quantitative reagents and immunochemical methods for the determination of multivalent antigens in liquid samples | |
| Lim | A one-step two-particle latex immunoassay for the detection of Salmonella typhi endotoxin | |
| Gerdes et al. | Influence of antibody valency in a displacement immunoassay for the quantitation of 2, 4-dichlorophenoxyacetic acid | |
| FI100557B (en) | Determination of free trypsinogen-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6 A 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |